Metastatic Castration Resistant Prostate Cancer Mcrpc clinical trials

Explore recruiting metastatic castration resistant prostate cancer mcrpc clinical trials.

Recruiting metastatic castration resistant prostate cancer mcrpc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Castration Resistant Prostate Cancer Mcrpc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and dose optimization study of GSK5471713 in adult participants with metastatic castration resistant prostate cancer (mCRPC).

Netherlands, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer

Belgium, Italy, Spain, Germany, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of JNJ-78278343, a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer

France, Belgium, Spain, Poland, Italy, Netherlands +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Darolutamide with Bipolar Androgen Therapy (BAT) for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) – the DaroBAT Trial

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase 1 Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Spain, Germany, Portugal

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Standard dosed abiraterone versus Therapeutic Drug Monitoring guided abiraterone dosing – The Adapt Abi trial

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Metastatic Castration Resistant Prostate Cancer Mcrpc trials by city

Metastatic Castration Resistant Prostate Cancer Mcrpc in Toronto Metastatic Castration Resistant Prostate Cancer Mcrpc in Vancouver Metastatic Castration Resistant Prostate Cancer Mcrpc in Montreal Metastatic Castration Resistant Prostate Cancer Mcrpc in Calgary Metastatic Castration Resistant Prostate Cancer Mcrpc in Edmonton Metastatic Castration Resistant Prostate Cancer Mcrpc in Ottawa Metastatic Castration Resistant Prostate Cancer Mcrpc in Winnipeg Metastatic Castration Resistant Prostate Cancer Mcrpc in Quebec City Metastatic Castration Resistant Prostate Cancer Mcrpc in Hamilton Metastatic Castration Resistant Prostate Cancer Mcrpc in Kitchener Metastatic Castration Resistant Prostate Cancer Mcrpc in London Metastatic Castration Resistant Prostate Cancer Mcrpc in Halifax Metastatic Castration Resistant Prostate Cancer Mcrpc in New York Metastatic Castration Resistant Prostate Cancer Mcrpc in Los Angeles Metastatic Castration Resistant Prostate Cancer Mcrpc in Chicago Metastatic Castration Resistant Prostate Cancer Mcrpc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease